Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN
Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir) compared Week-96 efficacy and safety of darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r). Treatment-experi...
Saved in:
Published in | Current HIV research Vol. 10; no. 2; p. 171 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.03.2012
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir) compared Week-96 efficacy and safety of darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r). Treatment-experienced, LPV-naive, HIV-1-infected patients were randomised to DRV/r 600/100 mg bid or LPV/r 400/100 mg bid plus optimised background regimen (≥ 2 NRTIs/NNRTIs). 595 patients were enrolled (mean baseline HIV-1 RNA: 4.30 log10 copies/mL; median CD4 count: 232 cells/mm3). At Week 96, more DRV/r than LPV/r patients achieved HIV-1 RNA < 400 copies/mL (66.8% versus 58.9% [intent-to-treat (ITT)/time-to-loss of virological response (TLOVR)], estimated difference 8.7%, 95% confidence interval [CI]: 0.7-16.7), demonstrating the primary endpoint of non-inferiority of DRV/r (p < 0.001); the difference in response was statistically significant (p = 0.034). For the secondary efficacy parameter (HIV-1 RNA < 50 copies/mL) at Week 96, response to DRV/r was 60.4% versus 55.2% for LPV/r (ITT-TLOVR), estimated difference 5.8%, 95% CI: -2.3-13.9. Virological failure (VF; HIV-1 RNA > 400 copies/mL) with DRV/r (13.8%) was nearly half that with LPV/r (25.6%). Discontinuations due to adverse events were 8.1% for both DRV/r and LPV/r. Treatment-related grade 2-4 diarrhoea was 8.1% (DRV/r) versus 15.2% (LPV/r). Increases in triglycerides and total cholesterol were less pronounced with DRV/r. At 96 weeks, noninferiority (HIV-1 RNA < 400 copies/mL) of DRV/r over LPV/r was maintained; the difference in response was statistically significant. VF rate and treatment-related grade 2-4 diarrhoea were lower with DRV/r versus LPV/r. |
---|---|
AbstractList | Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir) compared Week-96 efficacy and safety of darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r). Treatment-experienced, LPV-naive, HIV-1-infected patients were randomised to DRV/r 600/100 mg bid or LPV/r 400/100 mg bid plus optimised background regimen (≥ 2 NRTIs/NNRTIs). 595 patients were enrolled (mean baseline HIV-1 RNA: 4.30 log10 copies/mL; median CD4 count: 232 cells/mm3). At Week 96, more DRV/r than LPV/r patients achieved HIV-1 RNA < 400 copies/mL (66.8% versus 58.9% [intent-to-treat (ITT)/time-to-loss of virological response (TLOVR)], estimated difference 8.7%, 95% confidence interval [CI]: 0.7-16.7), demonstrating the primary endpoint of non-inferiority of DRV/r (p < 0.001); the difference in response was statistically significant (p = 0.034). For the secondary efficacy parameter (HIV-1 RNA < 50 copies/mL) at Week 96, response to DRV/r was 60.4% versus 55.2% for LPV/r (ITT-TLOVR), estimated difference 5.8%, 95% CI: -2.3-13.9. Virological failure (VF; HIV-1 RNA > 400 copies/mL) with DRV/r (13.8%) was nearly half that with LPV/r (25.6%). Discontinuations due to adverse events were 8.1% for both DRV/r and LPV/r. Treatment-related grade 2-4 diarrhoea was 8.1% (DRV/r) versus 15.2% (LPV/r). Increases in triglycerides and total cholesterol were less pronounced with DRV/r. At 96 weeks, noninferiority (HIV-1 RNA < 400 copies/mL) of DRV/r over LPV/r was maintained; the difference in response was statistically significant. VF rate and treatment-related grade 2-4 diarrhoea were lower with DRV/r versus LPV/r. |
Author | Bánhegyi, Dénes Vandevoorde, Ann Rachlis, Anita Schneider, Stefan Tomaka, Frank Katlama, Christine da Cunha, Clóvis Arns De Meyer, Sandra Workman, Cassy Van De Casteele, Tom |
Author_xml | – sequence: 1 givenname: Dénes surname: Bánhegyi fullname: Bánhegyi, Dénes email: denes.banhegyi@laszlokorhaz.hu organization: Szent László Hospital, Budapest, Hungary. denes.banhegyi@laszlokorhaz.hu – sequence: 2 givenname: Christine surname: Katlama fullname: Katlama, Christine – sequence: 3 givenname: Clóvis Arns surname: da Cunha fullname: da Cunha, Clóvis Arns – sequence: 4 givenname: Stefan surname: Schneider fullname: Schneider, Stefan – sequence: 5 givenname: Anita surname: Rachlis fullname: Rachlis, Anita – sequence: 6 givenname: Cassy surname: Workman fullname: Workman, Cassy – sequence: 7 givenname: Sandra surname: De Meyer fullname: De Meyer, Sandra – sequence: 8 givenname: Ann surname: Vandevoorde fullname: Vandevoorde, Ann – sequence: 9 givenname: Tom surname: Van De Casteele fullname: Van De Casteele, Tom – sequence: 10 givenname: Frank surname: Tomaka fullname: Tomaka, Frank |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22339125$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKAzEYhIMo9qAv4IXkAVy7ySab5LIUD4WiNxUvy5_kj6y22SWbFvftrWivZpgZBr4JOY9tREJuWHnPmRIzJlXJas64MsZUijN9RsZMq6oQXLIRmfT9Z1nyUit2SUacV5VhXI5Jekf8oqamGELjwA139NCkdtt-DBSipz0EzANtA_WQ9hGO5SzRA6Z-39Nt2zWnqIk0J4S8w5gL_O4wNRgdetpBPrrc_y7Wy_X85YpcBNj2eP2vU_L2-LBePBer16flYr4qrDA8F04aIX2tmZbKCg3gLEeHNlhQSnrmtdbSHwk9tyjqGnQAo5XQSgtXWcan5Pbvt9vbHfpNl5odpGFzguc_SiZdhg |
CitedBy_id | crossref_primary_10_1310_hct1504_151 crossref_primary_10_1080_23744235_2019_1694696 crossref_primary_10_3389_fphar_2019_01455 crossref_primary_10_1310_hct1305_256 crossref_primary_10_1128_AAC_01420_13 crossref_primary_10_1002_phar_2227 crossref_primary_10_1007_s40262_013_0040_2 crossref_primary_10_1093_cid_cis544 crossref_primary_10_1517_14656566_2015_1109632 crossref_primary_10_1093_cid_ciy382 crossref_primary_10_1007_s40265_018_0934_2 crossref_primary_10_1093_jac_dku509 crossref_primary_10_1586_14787210_2015_1033400 crossref_primary_10_1007_s40265_013_0159_3 crossref_primary_10_1038_s41598_018_23375_6 crossref_primary_10_1089_apc_2013_0159 crossref_primary_10_1631_jzus_B2000204 crossref_primary_10_1111_hiv_12298 crossref_primary_10_1007_s40268_018_0238_8 crossref_primary_10_1097_INF_0000000000000644 crossref_primary_10_1136_ejhpharm_2023_004015 crossref_primary_10_1080_17512433_2017_1390428 crossref_primary_10_1177_1060028018790574 crossref_primary_10_3111_13696998_2015_1046878 crossref_primary_10_1002_cpdd_88 crossref_primary_10_4269_ajtmh_15_0453 crossref_primary_10_3947_ic_2020_0124 crossref_primary_10_1093_jac_dky384 crossref_primary_10_1016_j_coph_2014_07_008 crossref_primary_10_1002_jcph_290 crossref_primary_10_1016_S2352_3018_18_30043_2 crossref_primary_10_1111_hiv_12366 crossref_primary_10_1111_hiv_12388 crossref_primary_10_1093_jac_dkaa072 crossref_primary_10_1177_2049936120920177 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.2174/157016212799937218 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Public Health Biology |
EISSN | 1873-4251 |
ExternalDocumentID | 22339125 |
Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .5. 0R~ 29F 36B 4.4 53G 5GY AAEGP ABEEF ABJNI ACGFS ACITR ACPRK AENEX AFRAH AFUQM AGJNZ ALMA_UNASSIGNED_HOLDINGS ANTIV C1A CGR CS3 CUY CVF EBS ECM EIF EJD F5P GH2 HZ~ IPNFZ KCGFV NPM O9- OVD P2P RIG TEORI ZA5 |
ID | FETCH-LOGICAL-b492t-c5945d681857b48aacb2ecebfba775d1d8885d873d2be466a8fa98748784c3b12 |
IngestDate | Thu May 23 23:15:05 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b492t-c5945d681857b48aacb2ecebfba775d1d8885d873d2be466a8fa98748784c3b12 |
PMID | 22339125 |
ParticipantIDs | pubmed_primary_22339125 |
PublicationCentury | 2000 |
PublicationDate | 2012-Mar |
PublicationDateYYYYMMDD | 2012-03-01 |
PublicationDate_xml | – month: 03 year: 2012 text: 2012-Mar |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Current HIV research |
PublicationTitleAlternate | Curr HIV Res |
PublicationYear | 2012 |
SSID | ssj0020871 |
Score | 2.157612 |
Snippet | Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 171 |
SubjectTerms | Adult CD4 Lymphocyte Count Darunavir Drug Therapy, Combination - methods Female HIV Infections - drug therapy HIV Infections - immunology HIV Infections - virology HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use HIV-1 - isolation & purification Humans Logistic Models Lopinavir - adverse effects Lopinavir - therapeutic use Male Middle Aged Ritonavir - adverse effects Ritonavir - therapeutic use RNA, Viral - analysis Sulfonamides - adverse effects Sulfonamides - therapeutic use Viral Load |
Title | Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22339125 |
Volume | 10 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2RUhICEF5tyAfuIW0m8RO4mO7Ai0gemEr9Vb5SYvArbK7SOWf8e86YyfZdCkIuESRnZc8nyYz9jefCXnFLRemUiKtIFZOWWFtKl2FzCkt5HjshAnbt308LKdH7P0xPx6Nfg5YS8uF2tU_bqwr-R-rQhvYFatk_8Gy_UOhAc7BvnAEC8Pxr2yMUruJKJGUAWOtw3hh3VovqzSXzkbKhZHN0kvohLc1CXIxlvMkVEv1jch47Gjnqe0lkE2nvRqYs7N3s1b_9ct12dIp5JGtclA_w3wQluEzf2o_X8aC9rgu71fExQ9yAZiUK52DwTq_kclk6eOK1OQr3npQfD-bJ_uN7-__pE89SnU1LWXNtWhvJzKQEdIxuXZtdL51VaTgQ7Jr3nk8QGE-cLVZ3Lpl_ReAKRbORvAKglmUrxcYgeXRyQ8wcfEtgAKio0Jksfb6z71rstxd1wbZqGp0rYc4TdRm-mNIQ2OFFn7O3q8fgxrU7QPW8pkQ18zuk3ttQkL3I7oekJH1W-R23KL0covcjfO6NJarPSQNYo6KknaYe007xFFAHI2Io-eO9ojba2jEG-3xBk1nnt6INtqhDa8IaHtEjt6-mU2mabtvR6qYyBep5oJxUwaZMcVqKbXKrbbKKVlV3GSmrmtuwNgmV5aVpaydFHUFqXPNdKGy_DHZ9OfePiVUYMKcaeG0YcwY-P9wqZkTFobYWVs-I0_i4J1cRHGWk25Yn_-2Z5vcWcFvh9xy4A3sCwgtF-plMOMVdhJ2kw |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Week+96+efficacy%2C+virology+and+safety+of+darunavir%2Fr+versus+lopinavir%2Fr+in+treatment-experienced+patients+in+TITAN&rft.jtitle=Current+HIV+research&rft.au=B%C3%A1nhegyi%2C+D%C3%A9nes&rft.au=Katlama%2C+Christine&rft.au=da+Cunha%2C+Cl%C3%B3vis+Arns&rft.au=Schneider%2C+Stefan&rft.date=2012-03-01&rft.eissn=1873-4251&rft.volume=10&rft.issue=2&rft.spage=171&rft_id=info:doi/10.2174%2F157016212799937218&rft_id=info%3Apmid%2F22339125&rft_id=info%3Apmid%2F22339125&rft.externalDocID=22339125 |